VYNE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.560 USD | -6.23% |
|
-13.22% | +9.87% |
| Nov. 18 | BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target | MT |
| Nov. 07 | Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000 | MT |
Evolution of the Average Target: VYNE Therapeutics Inc.
Evolution of the Target Price: VYNE Therapeutics Inc.
Changes in Analyst Recommendations: VYNE Therapeutics Inc.
e7.wWuQUL29VR6AVJJi52D36vejztKpNg7LQn8unn7G7W8.hCDjB4_bGSflHPE1tC3Fta_hjZPgeDyTJU5G_Uj2uEKsJ-UByI4EXe9kpg~61c4b7834a24a28fbbafc3478b9e097d
More recommendations
| Analyst Opinion | 4m Revision of opinion | Divergence of analysts' opinions | Divergence of Target Price | Ecart obj. / dr | ||
|---|---|---|---|---|---|---|
| +141.70% | ||||||
| +11.66% | ||||||
| +40.48% | ||||||
| -0.79% | ||||||
| +14.50% | ||||||
| +38.72% | ||||||
| +24.04% | ||||||
| +51.14% | ||||||
| +18.68% | ||||||
| +95.09% | ||||||
| Average | +43.52% | |||||
| Weighted average by Cap. | +24.73% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.560USD
Average target price
6.188USD
Spread / Average Target
+141.70%
High Price Target
8.000USD
Spread / Highest target
+212.50%
Low Price Target
5.000USD
Spread / Lowest Target
+95.31%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BTIG | |
| Cantor Fitzgerald | |
| HC Wainwright | |
| Northland Securities |
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VYNE Stock
- Consensus VYNE Therapeutics Inc.